We describe the case of a patient with a diagnosis of rheumatoid arthritis experiencing a mucocutaneous delayed reaction to golimumab. Anyway, there is no consensus regarding the best management of delayed reactions to biologics. Excluding allergic cross-reactivity or sensitization, we finally tested adalimumab by a graded challenge.

After a suspected allergic reactions to first dose of mRNA COVID-19 vaccine, given the PEG skin tests negativity and tolerance in vivo to PEG containing drugs, five patients were vaccinated with the second dose of Pfizer-Biontech undergoing a fractional protocol, with antihistamine premedication, without presenting immediate or delayed reactions.